BC Innovations | Feb 21, 2019
Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Studies in mice characterized two immunotoxins that could help treat BCMA-expressing MM. The immunotoxins consist of the cytotoxic Pseudomonas aeruginosa exotoxin domain III linked to a BCMA-targeting Fab fragment or variable...
BC Innovations | Sep 26, 2018
Distillery Therapeutics

Cancer

INDICATION: Sarcoma; pancreatic cancer In vitro and mouse studies identified an amiloride-based PLAU inhibitor that could help treat metastatic fibrosarcoma and pancreatic cancers. Chemical synthesis and in vitro testing of amiloride analogs in enzyme activity...
BC Week In Review | Nov 10, 2017
Financial News

Telix raises A$50M in Australian IPO

On Nov. 9, Telix Pharmaceuticals Ltd. (ASX:TLX) raised A$50 million ($38.3 million) through the sale of 77 million shares at A$0.65 in an IPO underwritten by Taylor Collison and Wilsons Corporate Finance. The price values...
BC Extra | Nov 9, 2017
Financial News

Telix raises A$50M in Australian IPO

Telix Pharmaceuticals Ltd. (ASX:TLX) raised A$50 million ($38.3 million) through the sale of 77 million shares at A$0.65 in an IPO underwritten by Taylor Collison and Wilsons Corporate Finance. The price values the company at...
BC Week In Review | Feb 10, 2017
Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

Wilex's Heidelberg Pharma GmbH subsidiary exercised an option under a 2016 deal to license humanized antibodies against tumor necrosis factor (TNF) receptor superfamily member 17 ( BCMA ; TNFRSF17 ; CD269). Heidelberg designated HDP-101 as the...
BC Week In Review | Jan 20, 2017
Company News

Wilex, Telix deal

Wilex granted newco Telix exclusive, worldwide rights to develop and commercialize Redectane (124-iodine-girentuximab). The radiolabeled WX-G250 antibody has completed one Phase III trial as a diagnostic imaging agent for clear cell renal cell carcinoma (RCC)....
BC Week In Review | Oct 31, 2016
Company News

Nordic Nanovector, Wilex deal

Nordic Nanovector and Wilex’s Heidelberg Pharma GmbH subsidiary partnered to develop antibody-drug conjugates (ADCs) to treat leukemia. Nordic Nanovector will provide an undisclosed antibody against leukemia cells, and Heidelberg Pharma will utilize its ADC technology...
BC Week In Review | Oct 17, 2016
Financial News

Financial News

Wilex AG...
BC Week In Review | Sep 26, 2016
Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

The Max Delbrueck Center ( MDC ) granted Wilex’s Heidelberg Pharma GmbH subsidiary an option to license humanized antibodies against tumor necrosis factor (TNF) receptor superfamily member 17 ( BCMA ; TNFRSF17 ; CD269 ). Heidelberg designated HDP-101...
BC Week In Review | Jun 27, 2016
Company News

Advanced Proteome Therapeutics, Wilex deal

Advanced Proteome and Wilex’s Heidelberg Pharma GmbH subsidiary partnered to create antibody-drug conjugates (ADCs) to treat cancer. Heidelberg will contribute its Antibody Targeted Amanitin Conjugates (ATACs) technology, and Advanced Proteome will provide its site-specific protein...
Items per page:
1 - 10 of 307
BC Innovations | Feb 21, 2019
Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Studies in mice characterized two immunotoxins that could help treat BCMA-expressing MM. The immunotoxins consist of the cytotoxic Pseudomonas aeruginosa exotoxin domain III linked to a BCMA-targeting Fab fragment or variable...
BC Innovations | Sep 26, 2018
Distillery Therapeutics

Cancer

INDICATION: Sarcoma; pancreatic cancer In vitro and mouse studies identified an amiloride-based PLAU inhibitor that could help treat metastatic fibrosarcoma and pancreatic cancers. Chemical synthesis and in vitro testing of amiloride analogs in enzyme activity...
BC Week In Review | Nov 10, 2017
Financial News

Telix raises A$50M in Australian IPO

On Nov. 9, Telix Pharmaceuticals Ltd. (ASX:TLX) raised A$50 million ($38.3 million) through the sale of 77 million shares at A$0.65 in an IPO underwritten by Taylor Collison and Wilsons Corporate Finance. The price values...
BC Extra | Nov 9, 2017
Financial News

Telix raises A$50M in Australian IPO

Telix Pharmaceuticals Ltd. (ASX:TLX) raised A$50 million ($38.3 million) through the sale of 77 million shares at A$0.65 in an IPO underwritten by Taylor Collison and Wilsons Corporate Finance. The price values the company at...
BC Week In Review | Feb 10, 2017
Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

Wilex's Heidelberg Pharma GmbH subsidiary exercised an option under a 2016 deal to license humanized antibodies against tumor necrosis factor (TNF) receptor superfamily member 17 ( BCMA ; TNFRSF17 ; CD269). Heidelberg designated HDP-101 as the...
BC Week In Review | Jan 20, 2017
Company News

Wilex, Telix deal

Wilex granted newco Telix exclusive, worldwide rights to develop and commercialize Redectane (124-iodine-girentuximab). The radiolabeled WX-G250 antibody has completed one Phase III trial as a diagnostic imaging agent for clear cell renal cell carcinoma (RCC)....
BC Week In Review | Oct 31, 2016
Company News

Nordic Nanovector, Wilex deal

Nordic Nanovector and Wilex’s Heidelberg Pharma GmbH subsidiary partnered to develop antibody-drug conjugates (ADCs) to treat leukemia. Nordic Nanovector will provide an undisclosed antibody against leukemia cells, and Heidelberg Pharma will utilize its ADC technology...
BC Week In Review | Oct 17, 2016
Financial News

Financial News

Wilex AG...
BC Week In Review | Sep 26, 2016
Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

The Max Delbrueck Center ( MDC ) granted Wilex’s Heidelberg Pharma GmbH subsidiary an option to license humanized antibodies against tumor necrosis factor (TNF) receptor superfamily member 17 ( BCMA ; TNFRSF17 ; CD269 ). Heidelberg designated HDP-101...
BC Week In Review | Jun 27, 2016
Company News

Advanced Proteome Therapeutics, Wilex deal

Advanced Proteome and Wilex’s Heidelberg Pharma GmbH subsidiary partnered to create antibody-drug conjugates (ADCs) to treat cancer. Heidelberg will contribute its Antibody Targeted Amanitin Conjugates (ATACs) technology, and Advanced Proteome will provide its site-specific protein...
Items per page:
1 - 10 of 307